Boston Pharma Inks 3-year Out-licenses And Option Agreement With GSK For Advancement Of Multiple Pre-phase 2 Programmes

Boston Pharma announced a pioneering three-year out-licenses and option agreement with GlaxoSmithKline (GSK). Boston Pharmaceuticals will become a preferred GSK partner for select pre-phase 2 programmes. This new agreement builds on the relationship established in 2018 with Boston Pharmaceuticals’ acquisition of five GSK programmes.“This new agreement validates Boston Pharmaceuticals as a trusted development partner with whom pharmaceutical companies can collaborate,” said Robert Armstrong, Ph.D., CEO of Boston Pharmaceuticals. “GSK has been an excellent partner and we look forward to advancing these pre-phase 2 assets into and through the clinic to evaluate their potential to improve patient lives.”Initially, GSK will out-license and option two programs to Boston Pharmaceuticals: GSK3903371 - a monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a tumor-associated antigen driving tumor growth and immunosuppression. GSK3502421 - an orally available, small molecule inhibitor for potential neurological disorders that targets Receptor Interacting Serine/Threonine Kinase 1 (RIPK1), a key component of the TNF-driven inflammation and necroptosis pathway.“We are pleased to further strengthen our relationship with Boston Pharmaceuticals as they continue to help us translate great science into medicines,” said John Lepore, SVP, and Research of GSK. “This agreement makes strong strategic sense as it helps us assess the potential of multiple early-stage programs and focus on progressing our own internal assets, while maintaining pipeline optionality for the future.”Under the agreement, Boston Pharmaceuticals will be responsible for further development of select programs through proof-of-concept (PoC). Following the completion of PoC studies, GSK will have the option to reacquire each programme under pre-agreed terms for subsequent development and worldwide commercialization.If GSK exercises its repurchase option, Boston Pharmaceuticals will receive a one-time payment, as well as be eligible for approval and sales milestones and royalties. In the event GSK chooses not to reacquire a program, Boston Pharmaceuticals may continue development and potential commercialization of the programme. GSK will then be eligible to receive milestones and royalty payments.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!